Admissions Committee Massimo Cristofanilli, MD, FACP Professor of Medicine Robert Lurie Cancer Center, Northwestern University Dr. Cristofanilli reciveived his medical degree in 1986 from the University “La Sapienza” Medical School in Rome (Italy) where he subsequently completed a Fellowship in Medical Oncology in November 1990. In July 1996, he started a Medical Oncology Fellowship at the University of Texas M. D. Anderson Cancer Center.
Educational Committee Prof. Dr. Christian Rolfo, MD, PhD, MBA He was born in Córdoba, Argentina in 1972; studied at the National University of Córdoba, graduating from the medical school in 1996. In 1998 he began his studies at the University of Milan, Italy.
Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica | GENYO · ONCOLOGICAL RESEARCH. CTC GROUP
TREASURER ISLB Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica | GENYO · NanochemBio
Hospital Universitario 12 de Octubre, Madrid, Spain Media Relations Committee Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), all in Madrid, Spain.
Clinical Implementation Committee He is the Scientific Coordinator of the Genomics Core Facility and Principal Investigator at the newly established i3S - Instituto de Investigação e Inovação em Saúde. His career has focused on understanding the crucial genetic events that are the basis for the development and progression of cancer. To develop his work, he uses diverse genomic techniques, ranging from basic molecular biology tools to high-throughput technologies.
Computational Committee Director of the Bioinformatics Area, Fundacion Progreso y Salud, Sevilla, Spain Clinical Bioinformatics Area, Fundacion Progreso y Salud, CDCA, Hospital Virgen del Rocío, C/Manuel Siurot s/n. Seville, Spain
Audit Committee University Cancer Institute “OncoHealth” University Hospital “Fundacion Jimenez Diaz” Autonomous University of Madrid, Spain
Liquid Biopsy Samples Repository Committee Chairman of Oncology Department Codirector of the Lung Cancer Program Associate Professor of Oncology (School of Medicine, University of Navarra) Principal investigator at the Center for Applied Medical Research (CIMA)
Publications Committee Ignacio Durán, MD, PhD Hospital Universitario ‘Virgen del Rocio’ Seville, Spain Dr Durán is a member of the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Spanish Society of Medical Oncology. His major research interests include genitourinary tumours and anticancer clinical drug development. He has authored numerous publications covering diverse areas of medical oncology in peer-reviewed scientific journals.
Grants And Prizes Committee Eduardo Díaz-Rubio Catedrático y Jefe Servicio Oncología Médica Académico de Número de la Real Academia Nacional de Medicina Hospital Universitario Clínico San Carlos Facultad de Medicina, Universidad Complutense, Madrid.
Chair of Young Investigators Assistant Professor in Anatomic Pathology in School of Medicine. Department of Public Health, University Federico II of Naples
University of Antwerpen Belgium
Professor of Analytical Chemistry – Clinical Chemistry Dr. Evi Lianidou is Professor of Analytical Chemistry and Clinical Chemistry at the Department of Chemistry, University of Athens, Greece. Dr Lianidou has established a Molecular Diagnostics Laboratory focused on Liquid Biopsy at the Department of Chemistry since 1998
University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA David R. Gandara, MD is a Professor of Medicine at the University of California at Davis (UCD) School of Medicine, is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at UC Davis Comprehensive Cancer Center (UCDCCC). He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology.
Fundación Hospital General Universitario de Valencia · Molecular Oncology, Spain
MD Anderson, Spain
Licenciado en Medicina y Cirugía. Universidad de Granada y Especialista en Neumología (Hospital Universitario Virgen de las Nieves de Granada). Actualmente es Facultativo Especialista de Neumología en el Hospital de Alta Resolución de Loja (Granada). Su investigación clínica se centra en EPOC y asma bronquial, en la identificación de biomarcadores de respuesta al tratamiento inhalado en la EPOC, así como patrones de aparición de exacerbaciones frecuentes y consumo de recursos sanitarios.
Dr Leticia De Mattos-Arruda, MD, PhD is a physician scientist medical oncologist at the Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. She worked at the VHIO conducting clinical trials and translational research projects from 2009 to 2014. In 2010, she was a recipient of the European Society for Medical Oncology (ESMO) Translational Research Fellowship and attended the 12o ECCO - AACR - EORTC - ESMO Workshop on Methods in Clinical Cancer Research.
Medical Oncologists Pangaea Oncology Barcelona, Spain
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine MD Anderson
MD Anderson Professor and Chairman, Department of Cancer Biology University of Texas MD Anderson Cancer Center *Adjunct Professor of Molecular and Cellular Biology Baylor College of Medicine *Adjunct Professor of Bioengineering Rice University
Università degli Studi di Palermo, Palermo Italy
Huntsman Cancer Institute- University of Utah, USA. The research of Manish Kohli, M.D., is focused on identifying biomarkers with predictive and prognostic impact in patients with advanced prostate cancer, advanced kidney cancer, advanced bladder cancer and all stages of testicular cancer. In the Division of Medical Oncology at Mayo Clinic, Dr. Kohli also conducts and oversees phase I, II and III clinical trials in the advanced stages of these malignancies.
Cancer Research, Education and Public Policy Advocate Director of Research and Advocacy Inflammatory Breast Cancer International Consortium (ibcic.org) Valerie serves as Officer and Director of Research and Advocacy for the Inflammatory Breast Cancer International Consortium (ibcic.org). As a cancer research advocate she has served on clinical trial working groups, scientific review panels, agent selection committees, steering committees and advisory groups and as an advocate consultant and peer
Körperschaft des öffentlichen Rechts; Gerichtsstand, Germany
Institut Curie, France
Istituto Oncologico Veneto Italy
Université de Sciencies Montpellier, France
Parc de Salut Mar Barcelona, Spain
University Magna Graecia
Todd E. Druley, MD, PhD is the Chief Medical Officer for ArcherDX, Inc. He is also an Associate Professor of Pediatrics, Genetics and Developmental Biology at Washington University School of Medicine in St. Louis. His work focuses on improved molecular diagnostics for precision cancer therapy as well as pediatric cancer predisposition.
El Dr. García Giménez se licenció en Ciencias Químicas en 2002 y dos años después obtuvo su licenciatura en Bioquímica por la Universitat de València. En el año 2007 finalizó su tesis doctoral en el Departamento de Química Inorgánica de la Facultat de Farmacia obteniendo el grado de doctor con sobresaliente “cum laude”. es investigador post-doctoral del Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) e Investigador del Instituto de Investigación Sanitaria INCLIVA
Oncogenomic and Epigenetic Unit Department of Research, Advanced diagnostics and Technological innovation IRCSS Regina Elena National Cancer Institute Via E. Chianesi 53, 00144, Rome
University Hospital Essen Germany
Oxford Brookes University UK graduated in 2015 with a 1st Class Honours with Distinction BSc/MSc in Chemistry and Pharmaceutical Technology at the University of Naples Federico II. I then undertook lab placements at Swansea, Newcastle and Cambridge Universities where I specialized in cancer biology and metastasis research. I then started to work in the Carter lab in 2017.
Lauren Leiman, MBA Bloodpac USA
Tim is both Head of Science and Innovation and co-founder of Inivata. He is also an honorary lecturer at UCL. Prior to Inivata, during his time at Cambridge University and Cancer Research UK, Tim was part of the team that first published detecting solid tumour mutations through next generation sequencing of cell free DNA. As a postdoctoral Researcher he won the 2009 Jeremy Jass Prize for his role in identifying fusion genes in Pilocytic Astrocytoma.